Given the upregulation of FTO in breast cancer and its potential role in cancer initiation and progression, we examined the effects of FB23, a potent FTO inhibitor that exhibits 140-fold greater efficacy than MA in inhibiting FTO-mediated demethylation 12, on breast cancer cells. The gene discussed is FTO; the disease is breast carcinoma.